Jeremy Bender - 15 Aug 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
15 Aug 2022
Transactions value $
-$97,313
Form type
4
Filing time
17 Aug 2022, 19:24:53 UTC
Previous filing
05 Aug 2022
Next filing
06 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise $0 +10,686 +0.86% $0.000000 1,256,878 15 Aug 2022 Direct
transaction DAWN Common Stock Sale -$97,312 -4,003 -0.32% $24.31 1,252,875 16 Aug 2022 Direct F1
holding DAWN Common Stock 281,574 15 Aug 2022 See Footnote F2
holding DAWN Common Stock 281,574 15 Aug 2022 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -10,686 -18.7% $0.000000 46,314 15 Aug 2022 Common Stock 10,686 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").
F2 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F3 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
F4 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F5 The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.